Review



proteome profiler apoptotic array kit  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    R&D Systems proteome profiler apoptotic array kit
    A. Oral cancer cell line H357 sensitive and H357cisR was seeded on 6 well plates and treated with different concentrations 5, 10, and 15 ug mL-1. With respect to time, the cell morphology changes and becomes rounded in shape, and at higher concentration cell starts to detach from the surface. B. H357CisR cells were treated with indicated dose of TDEF for 48 hrs after which cell death was determined by annexin V/7AAD assay using flow cytometer. The dot plots represent the percentage of early <t>apoptotic</t> (lower right) and late apoptotic cells (upper right). C. Bar diagrams indicate the percentage of cell death; black color portion indicates percentage of early apoptosis and grey color indicates percentage of late apoptosis occur with respective treated groups. D. TDEF treated H357cisR cell pellet was fixed with 70% ethanol and stained with propidium iodide and the cell distribution in different cell cycle phases was analyzed by FACS. Cell cycle arrest was shown highest at 10 ug mL-1 but the cell with the higher concentration of extract has experience apoptosis and necrosis. The percentage of the G1 population was found to be 65.1%, and the control G1 cell population was 47.8%.
    Proteome Profiler Apoptotic Array Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 261 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+array/pmc10998759-175-11-17?v=R%26D+Systems
    Average 96 stars, based on 261 article reviews
    proteome profiler apoptotic array kit - by Bioz Stars, 2026-08
    96/100 stars

    Images

    1) Product Images from "Tolypothrix Dichloromethane Ethylacetate fraction (TDEF) inhibits cisplatin resistance H357 cell through PI3K/AKT/beta-catenin pathway"

    Article Title: Tolypothrix Dichloromethane Ethylacetate fraction (TDEF) inhibits cisplatin resistance H357 cell through PI3K/AKT/beta-catenin pathway

    Journal: American Journal of Cancer Research

    doi: 10.62347/JTNQ4812

    A. Oral cancer cell line H357 sensitive and H357cisR was seeded on 6 well plates and treated with different concentrations 5, 10, and 15 ug mL-1. With respect to time, the cell morphology changes and becomes rounded in shape, and at higher concentration cell starts to detach from the surface. B. H357CisR cells were treated with indicated dose of TDEF for 48 hrs after which cell death was determined by annexin V/7AAD assay using flow cytometer. The dot plots represent the percentage of early apoptotic (lower right) and late apoptotic cells (upper right). C. Bar diagrams indicate the percentage of cell death; black color portion indicates percentage of early apoptosis and grey color indicates percentage of late apoptosis occur with respective treated groups. D. TDEF treated H357cisR cell pellet was fixed with 70% ethanol and stained with propidium iodide and the cell distribution in different cell cycle phases was analyzed by FACS. Cell cycle arrest was shown highest at 10 ug mL-1 but the cell with the higher concentration of extract has experience apoptosis and necrosis. The percentage of the G1 population was found to be 65.1%, and the control G1 cell population was 47.8%.
    Figure Legend Snippet: A. Oral cancer cell line H357 sensitive and H357cisR was seeded on 6 well plates and treated with different concentrations 5, 10, and 15 ug mL-1. With respect to time, the cell morphology changes and becomes rounded in shape, and at higher concentration cell starts to detach from the surface. B. H357CisR cells were treated with indicated dose of TDEF for 48 hrs after which cell death was determined by annexin V/7AAD assay using flow cytometer. The dot plots represent the percentage of early apoptotic (lower right) and late apoptotic cells (upper right). C. Bar diagrams indicate the percentage of cell death; black color portion indicates percentage of early apoptosis and grey color indicates percentage of late apoptosis occur with respective treated groups. D. TDEF treated H357cisR cell pellet was fixed with 70% ethanol and stained with propidium iodide and the cell distribution in different cell cycle phases was analyzed by FACS. Cell cycle arrest was shown highest at 10 ug mL-1 but the cell with the higher concentration of extract has experience apoptosis and necrosis. The percentage of the G1 population was found to be 65.1%, and the control G1 cell population was 47.8%.

    Techniques Used: Concentration Assay, Flow Cytometry, Staining, Control

    A. The Pp53 and P21 signalling pathways are strongly activated by TDEF treatment. The human apoptosis proteome profiler array used a protein extract (400 µg). The intensities of each array spot were visualized and further quantified using an image. B. The graph shows the relative fold change of proteins with significant differences upon TDEF treatment, setting 1 for control (no treatment of TDEF). Protein levels with higher than ± 2 folds are considered candidates for TDEF-induced cell death.
    Figure Legend Snippet: A. The Pp53 and P21 signalling pathways are strongly activated by TDEF treatment. The human apoptosis proteome profiler array used a protein extract (400 µg). The intensities of each array spot were visualized and further quantified using an image. B. The graph shows the relative fold change of proteins with significant differences upon TDEF treatment, setting 1 for control (no treatment of TDEF). Protein levels with higher than ± 2 folds are considered candidates for TDEF-induced cell death.

    Techniques Used: Control



    Similar Products

    90
    Eve Technologies Corporation human high sensitivity t-cell discovery array 14-plex (hdhstc14
    Human High Sensitivity T Cell Discovery Array 14 Plex (Hdhstc14, supplied by Eve Technologies Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+array/nct05806385-145-18-10?v=Eve+Technologies+Corporation
    Average 90 stars, based on 1 article reviews
    human high sensitivity t-cell discovery array 14-plex (hdhstc14 - by Bioz Stars, 2026-08
    90/100 stars
      Buy from Supplier

    90
    Thermo Fisher human exon 1.0st array
    Human Exon 1.0st Array, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+array/nct04134260-8-18--1?v=Thermo+Fisher
    Average 90 stars, based on 1 article reviews
    human exon 1.0st array - by Bioz Stars, 2026-08
    90/100 stars
      Buy from Supplier

    95
    R&D Systems proteome profiler human protease array
    Proteome Profiler Human Protease Array, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+array/pmc13019076-417-4-10?v=R%26D+Systems
    Average 95 stars, based on 1 article reviews
    proteome profiler human protease array - by Bioz Stars, 2026-08
    95/100 stars
      Buy from Supplier

    96
    R&D Systems proteome profiler human angiogenesis kit ary007
    Proteome Profiler Human Angiogenesis Kit Ary007, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+array/pmc12924898-210-7-13?v=R%26D+Systems
    Average 96 stars, based on 1 article reviews
    proteome profiler human angiogenesis kit ary007 - by Bioz Stars, 2026-08
    96/100 stars
      Buy from Supplier

    94
    OriGene healthy brain tissue
    Healthy Brain Tissue, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+array/pm42236120-298-30-39?v=OriGene
    Average 94 stars, based on 1 article reviews
    healthy brain tissue - by Bioz Stars, 2026-08
    94/100 stars
      Buy from Supplier

    86
    Biomax Inc human paraffin embedded tissue array
    Human Paraffin Embedded Tissue Array, supplied by Biomax Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+array/pm42167395-69-8-15?v=Biomax+Inc
    Average 86 stars, based on 1 article reviews
    human paraffin embedded tissue array - by Bioz Stars, 2026-08
    86/100 stars
      Buy from Supplier

    86
    Eve Technologies Corporation human cytokine chemokine 96 plex discovery assay array hd96 panel
    Hyperoxia‐induced senescent fASM secrete higher levels of SASP. Cells cultured till day 7 in normoxic (21% O 2 ) or hyperoxic (50% O 2 ) environment were incubated with fresh growth media in normoxia for 24 h, and the supernatants were collected. Samples were then analyzed for SASP secretion by Eve Technologies Corporation (Calgary, Alberta, Canada) using Luminex xMAP and the Human <t>Cytokine/Chemokine</t> <t>96‐Plex</t> Discovery Assay Array <t>(HD96)</t> panel. (A) Out of the 96 proteins, 80 were detected and visualized using a heatmap. (B) A detailed analysis of each detected marker is shown as fold‐change normalized to control. For statistical analysis, 2‐way ANOVA with a two‐stage linear step‐up procedure of Benjamini, Krieger and Yekutieli test, with individual variances computed for each comparison was applied. False discovery rate < 0.05 was considered significant. Data are presented as box plot of n = 7 cell lines per group.
    Human Cytokine Chemokine 96 Plex Discovery Assay Array Hd96 Panel, supplied by Eve Technologies Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+array/pmc13154765-167-24-16?v=Eve+Technologies+Corporation
    Average 86 stars, based on 1 article reviews
    human cytokine chemokine 96 plex discovery assay array hd96 panel - by Bioz Stars, 2026-08
    86/100 stars
      Buy from Supplier

    86
    Eve Technologies Corporation human cytokine chemokine 71 plex discovery assay array
    Hyperoxia‐induced senescent fASM secrete higher levels of SASP. Cells cultured till day 7 in normoxic (21% O 2 ) or hyperoxic (50% O 2 ) environment were incubated with fresh growth media in normoxia for 24 h, and the supernatants were collected. Samples were then analyzed for SASP secretion by Eve Technologies Corporation (Calgary, Alberta, Canada) using Luminex xMAP and the Human <t>Cytokine/Chemokine</t> <t>96‐Plex</t> Discovery Assay Array <t>(HD96)</t> panel. (A) Out of the 96 proteins, 80 were detected and visualized using a heatmap. (B) A detailed analysis of each detected marker is shown as fold‐change normalized to control. For statistical analysis, 2‐way ANOVA with a two‐stage linear step‐up procedure of Benjamini, Krieger and Yekutieli test, with individual variances computed for each comparison was applied. False discovery rate < 0.05 was considered significant. Data are presented as box plot of n = 7 cell lines per group.
    Human Cytokine Chemokine 71 Plex Discovery Assay Array, supplied by Eve Technologies Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+array/bio_rxiv__64898__2026__05__01__722277-62-26-17?v=Eve+Technologies+Corporation
    Average 86 stars, based on 1 article reviews
    human cytokine chemokine 71 plex discovery assay array - by Bioz Stars, 2026-08
    86/100 stars
      Buy from Supplier

    96
    R&D Systems proteome profiler human cytokine array kit
    Occludin modulates LPS-induced IL-8 secretion, barrier integrity, and cytoskeletal remodeling in human bronchial epithelial cells. (A) The BEAS-2b cells were transfected and were then incubated with LPS in a time-dependent manner before the generation of total cell lysates, and occludin transcripts were assessed by qRT-PCR. ∗ p < 0.05 compared to the control. (B) The cells were treated with LPS in a time-dependent manner. The occludin-specific antibody was assessed by Western blot analysis. β-actin was used as a loading control. (C) A construct expressing wild-type occludin or siRNA-occludin was transiently transfected into BEAS-2b cells. The cells were washed and serum-starved overnight. They were subsequently treated with LPS for 2 h and a <t>cytokine</t> assay was performed with cultured media and cell lysates were harvested for qRT-PCR of IL-8 (D) . The density of the resulting spots of IL-8 was measured using a densitometric analysis. ∗ p < 0.05 compared with control; ∗∗ p < 0.05 compared with LPS treatment; ∗∗∗ p < 0.05 compared with WT occludin-treated transfectants. (E) The cells were transfected with either the wild-type occludin construct or siRNA-occuldin before incubation with LPS for various times, and then TEER testing was performed. Error bars represent the SEM of at least three independent experiments. (F) Cells were then treated with LPS for 2 h. F-actin staining was performed using ActinRed 555 ReadyProbe reagent (Molecular Probes) following the manufacturer's instructions. Cell nuclei were stained with diluted Deep Red (1:300). The fluorescence intensity was analyzed and statistically evaluated (right panel). ∗ p < 0.05 compared with control; ∗∗ p < 0.05 compared with LPS treatment; ∗∗∗ p < 0.05 compared with WT occludin-treated transfectants. All data are representative of at least three independent experiments.
    Proteome Profiler Human Cytokine Array Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+array/pmc12996814-57-0-9?v=R%26D+Systems
    Average 96 stars, based on 1 article reviews
    proteome profiler human cytokine array kit - by Bioz Stars, 2026-08
    96/100 stars
      Buy from Supplier

    96
    R&D Systems proteome profiler human phospho kinase array kit
    Occludin modulates LPS-induced IL-8 secretion, barrier integrity, and cytoskeletal remodeling in human bronchial epithelial cells. (A) The BEAS-2b cells were transfected and were then incubated with LPS in a time-dependent manner before the generation of total cell lysates, and occludin transcripts were assessed by qRT-PCR. ∗ p < 0.05 compared to the control. (B) The cells were treated with LPS in a time-dependent manner. The occludin-specific antibody was assessed by Western blot analysis. β-actin was used as a loading control. (C) A construct expressing wild-type occludin or siRNA-occludin was transiently transfected into BEAS-2b cells. The cells were washed and serum-starved overnight. They were subsequently treated with LPS for 2 h and a <t>cytokine</t> assay was performed with cultured media and cell lysates were harvested for qRT-PCR of IL-8 (D) . The density of the resulting spots of IL-8 was measured using a densitometric analysis. ∗ p < 0.05 compared with control; ∗∗ p < 0.05 compared with LPS treatment; ∗∗∗ p < 0.05 compared with WT occludin-treated transfectants. (E) The cells were transfected with either the wild-type occludin construct or siRNA-occuldin before incubation with LPS for various times, and then TEER testing was performed. Error bars represent the SEM of at least three independent experiments. (F) Cells were then treated with LPS for 2 h. F-actin staining was performed using ActinRed 555 ReadyProbe reagent (Molecular Probes) following the manufacturer's instructions. Cell nuclei were stained with diluted Deep Red (1:300). The fluorescence intensity was analyzed and statistically evaluated (right panel). ∗ p < 0.05 compared with control; ∗∗ p < 0.05 compared with LPS treatment; ∗∗∗ p < 0.05 compared with WT occludin-treated transfectants. All data are representative of at least three independent experiments.
    Proteome Profiler Human Phospho Kinase Array Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+array/pm42031710-119-7-13?v=R%26D+Systems
    Average 96 stars, based on 1 article reviews
    proteome profiler human phospho kinase array kit - by Bioz Stars, 2026-08
    96/100 stars
      Buy from Supplier

    Image Search Results


    Hyperoxia‐induced senescent fASM secrete higher levels of SASP. Cells cultured till day 7 in normoxic (21% O 2 ) or hyperoxic (50% O 2 ) environment were incubated with fresh growth media in normoxia for 24 h, and the supernatants were collected. Samples were then analyzed for SASP secretion by Eve Technologies Corporation (Calgary, Alberta, Canada) using Luminex xMAP and the Human Cytokine/Chemokine 96‐Plex Discovery Assay Array (HD96) panel. (A) Out of the 96 proteins, 80 were detected and visualized using a heatmap. (B) A detailed analysis of each detected marker is shown as fold‐change normalized to control. For statistical analysis, 2‐way ANOVA with a two‐stage linear step‐up procedure of Benjamini, Krieger and Yekutieli test, with individual variances computed for each comparison was applied. False discovery rate < 0.05 was considered significant. Data are presented as box plot of n = 7 cell lines per group.

    Journal: Aging Cell

    Article Title: Targeting Hyperoxia‐Induced Cellular Senescence in Developing Human Airway Cells: Senomorphics Versus Senolytics Versus Antioxidants

    doi: 10.1111/acel.70538

    Figure Lengend Snippet: Hyperoxia‐induced senescent fASM secrete higher levels of SASP. Cells cultured till day 7 in normoxic (21% O 2 ) or hyperoxic (50% O 2 ) environment were incubated with fresh growth media in normoxia for 24 h, and the supernatants were collected. Samples were then analyzed for SASP secretion by Eve Technologies Corporation (Calgary, Alberta, Canada) using Luminex xMAP and the Human Cytokine/Chemokine 96‐Plex Discovery Assay Array (HD96) panel. (A) Out of the 96 proteins, 80 were detected and visualized using a heatmap. (B) A detailed analysis of each detected marker is shown as fold‐change normalized to control. For statistical analysis, 2‐way ANOVA with a two‐stage linear step‐up procedure of Benjamini, Krieger and Yekutieli test, with individual variances computed for each comparison was applied. False discovery rate < 0.05 was considered significant. Data are presented as box plot of n = 7 cell lines per group.

    Article Snippet: Supernatants collected at day 8 from normoxia and hyperoxia‐exposed fASM were analyzed for SASP secretion by Eve Technologies Corporation (Calgary, Alberta, Canada) using the Human Cytokine/Chemokine 96‐Plex Discovery Assay Array (HD96) panel.

    Techniques: Cell Culture, Incubation, Luminex, Marker, Control, Comparison

    Occludin modulates LPS-induced IL-8 secretion, barrier integrity, and cytoskeletal remodeling in human bronchial epithelial cells. (A) The BEAS-2b cells were transfected and were then incubated with LPS in a time-dependent manner before the generation of total cell lysates, and occludin transcripts were assessed by qRT-PCR. ∗ p < 0.05 compared to the control. (B) The cells were treated with LPS in a time-dependent manner. The occludin-specific antibody was assessed by Western blot analysis. β-actin was used as a loading control. (C) A construct expressing wild-type occludin or siRNA-occludin was transiently transfected into BEAS-2b cells. The cells were washed and serum-starved overnight. They were subsequently treated with LPS for 2 h and a cytokine assay was performed with cultured media and cell lysates were harvested for qRT-PCR of IL-8 (D) . The density of the resulting spots of IL-8 was measured using a densitometric analysis. ∗ p < 0.05 compared with control; ∗∗ p < 0.05 compared with LPS treatment; ∗∗∗ p < 0.05 compared with WT occludin-treated transfectants. (E) The cells were transfected with either the wild-type occludin construct or siRNA-occuldin before incubation with LPS for various times, and then TEER testing was performed. Error bars represent the SEM of at least three independent experiments. (F) Cells were then treated with LPS for 2 h. F-actin staining was performed using ActinRed 555 ReadyProbe reagent (Molecular Probes) following the manufacturer's instructions. Cell nuclei were stained with diluted Deep Red (1:300). The fluorescence intensity was analyzed and statistically evaluated (right panel). ∗ p < 0.05 compared with control; ∗∗ p < 0.05 compared with LPS treatment; ∗∗∗ p < 0.05 compared with WT occludin-treated transfectants. All data are representative of at least three independent experiments.

    Journal: Redox Biology

    Article Title: Prophylactic C-terminal occludin–derived peptide attenuates LPS-induced airway inflammation via barrier preservation and mitochondrial ROS regulation

    doi: 10.1016/j.redox.2026.104119

    Figure Lengend Snippet: Occludin modulates LPS-induced IL-8 secretion, barrier integrity, and cytoskeletal remodeling in human bronchial epithelial cells. (A) The BEAS-2b cells were transfected and were then incubated with LPS in a time-dependent manner before the generation of total cell lysates, and occludin transcripts were assessed by qRT-PCR. ∗ p < 0.05 compared to the control. (B) The cells were treated with LPS in a time-dependent manner. The occludin-specific antibody was assessed by Western blot analysis. β-actin was used as a loading control. (C) A construct expressing wild-type occludin or siRNA-occludin was transiently transfected into BEAS-2b cells. The cells were washed and serum-starved overnight. They were subsequently treated with LPS for 2 h and a cytokine assay was performed with cultured media and cell lysates were harvested for qRT-PCR of IL-8 (D) . The density of the resulting spots of IL-8 was measured using a densitometric analysis. ∗ p < 0.05 compared with control; ∗∗ p < 0.05 compared with LPS treatment; ∗∗∗ p < 0.05 compared with WT occludin-treated transfectants. (E) The cells were transfected with either the wild-type occludin construct or siRNA-occuldin before incubation with LPS for various times, and then TEER testing was performed. Error bars represent the SEM of at least three independent experiments. (F) Cells were then treated with LPS for 2 h. F-actin staining was performed using ActinRed 555 ReadyProbe reagent (Molecular Probes) following the manufacturer's instructions. Cell nuclei were stained with diluted Deep Red (1:300). The fluorescence intensity was analyzed and statistically evaluated (right panel). ∗ p < 0.05 compared with control; ∗∗ p < 0.05 compared with LPS treatment; ∗∗∗ p < 0.05 compared with WT occludin-treated transfectants. All data are representative of at least three independent experiments.

    Article Snippet: Proteome Profiler Human Cytokine Array kit was purchased from R&D Systems (cat no. ARY005B, USA).

    Techniques: Transfection, Incubation, Quantitative RT-PCR, Control, Western Blot, Construct, Expressing, Cytokine Assay, Cell Culture, Staining, Fluorescence

    The peptide regulates mitochondrial dysfunction and ROS production by inhibiting LPS-induced p38 activation. (A) The BEAS-2b cells were treated with wild-type occludin peptide (pepWT OCLN) or mutant occludin peptide (pepMut OCLN) and incubated with LPS for 15, 30 min. The phospho-specific and total antibodies were assessed by Western blot analysis. β-actin was used as a loading control. (B) The BEAS-2b cells were transfected with p38 overexpression construct (WT p38) or siRNA-p38 for 24 h and incubated with LPS for 4 h siRNA-scramble was used as a negative control. The proinflammatory cytokine transcripts were assessed by qRT-PCR. ∗ p < 0.05 compared with control; ∗∗ p < 0.05 compared with LPS treatment; ∗∗∗ p < 0.05 compared with WT p38-transfected cells. (C) The mitochondrial membrane potential of LPS-induced BEAS-2b cells treated with either WT OCLN peptide or mut peptide was stained with JC-1 dye. Images are representative results of 3 independent experiments. (D) The mitochondria fission was stained using phospho-Drp1 antibody and visualized. The fluorescence intensity was analyzed and statistically evaluated (right panel). ∗ p < 0.05 compared with control; ∗∗ p < 0.05 compared with LPS treatment; ∗∗∗ p < 0.05 compared with WT OCLN peptide-treated transfectants. (E) After the BEAS-2b cells were harvested, cell lysates were used for MTT assay. (F) After mitochondria from the cells was isolated, the mitochondria lysates were used for mtROS measurement. ∗ p < 0.05 compared with control; ∗∗ p < 0.05 compared with LPS only; ∗∗∗ p < 0.05 compared with LPS- and WT occludin peptide-treated cells. All data shown are representative of three independent experiments.

    Journal: Redox Biology

    Article Title: Prophylactic C-terminal occludin–derived peptide attenuates LPS-induced airway inflammation via barrier preservation and mitochondrial ROS regulation

    doi: 10.1016/j.redox.2026.104119

    Figure Lengend Snippet: The peptide regulates mitochondrial dysfunction and ROS production by inhibiting LPS-induced p38 activation. (A) The BEAS-2b cells were treated with wild-type occludin peptide (pepWT OCLN) or mutant occludin peptide (pepMut OCLN) and incubated with LPS for 15, 30 min. The phospho-specific and total antibodies were assessed by Western blot analysis. β-actin was used as a loading control. (B) The BEAS-2b cells were transfected with p38 overexpression construct (WT p38) or siRNA-p38 for 24 h and incubated with LPS for 4 h siRNA-scramble was used as a negative control. The proinflammatory cytokine transcripts were assessed by qRT-PCR. ∗ p < 0.05 compared with control; ∗∗ p < 0.05 compared with LPS treatment; ∗∗∗ p < 0.05 compared with WT p38-transfected cells. (C) The mitochondrial membrane potential of LPS-induced BEAS-2b cells treated with either WT OCLN peptide or mut peptide was stained with JC-1 dye. Images are representative results of 3 independent experiments. (D) The mitochondria fission was stained using phospho-Drp1 antibody and visualized. The fluorescence intensity was analyzed and statistically evaluated (right panel). ∗ p < 0.05 compared with control; ∗∗ p < 0.05 compared with LPS treatment; ∗∗∗ p < 0.05 compared with WT OCLN peptide-treated transfectants. (E) After the BEAS-2b cells were harvested, cell lysates were used for MTT assay. (F) After mitochondria from the cells was isolated, the mitochondria lysates were used for mtROS measurement. ∗ p < 0.05 compared with control; ∗∗ p < 0.05 compared with LPS only; ∗∗∗ p < 0.05 compared with LPS- and WT occludin peptide-treated cells. All data shown are representative of three independent experiments.

    Article Snippet: Proteome Profiler Human Cytokine Array kit was purchased from R&D Systems (cat no. ARY005B, USA).

    Techniques: Activation Assay, Mutagenesis, Incubation, Western Blot, Control, Transfection, Over Expression, Construct, Negative Control, Quantitative RT-PCR, Membrane, Staining, Fluorescence, MTT Assay, Isolation